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Purpose: This phase III study compared docetaxel
and doxorubicin in patients with metastatic breast can-
cer who had received previous alkylating agent–contain-
ing chemotherapy.
Patients and Methods: Patients were randomized to
receive an intravenous infusion of docetaxel 100 mg/m2
or doxorubicin 75 mg/m2 every 3 weeks for a maxi-
mum of seven treatment cycles.
Results: A total of 326 patients were randomized,
165 to receive doxorubicin and 161 to receive doce-
taxel. Overall, docetaxel produced a significantly higher
rate of objective response than did doxorubicin (47.8%
v 33.3%; P 5 .008). Docetaxel was also significantly
more active than doxorubicin in patients with negative
prognostic factors, such as visceral metastases (objec-
tive response, 46% v 29%) and resistance to prior
chemotherapy (47% v 25%). Median time to progres-
sion was longer in the docetaxel group (26 weeks v 21
weeks; difference not significant). Median overall sur-
vival was similar in the two groups (docetaxel, 15
months; doxorubicin, 14 months). There was one death
due to infection in each group, and an additional four
deaths due to cardiotoxicity in the doxorubicin group.
Although neutropenia was similar in both groups, fe-
brile neutropenia and severe infection occurred more
frequently in the doxorubicin group. For severe nonhe-
matologic toxicity, the incidences of cardiac toxicity,
nausea, vomiting, and stomatitis were higher among
patients receiving doxorubicin, whereas diarrhea, neu-
ropathy, fluid retention, and skin and nail changes were
higher among patients receiving docetaxel.
Conclusion: The observed differences in activity and
toxicity profiles provide a basis for therapy choice and
confirms the rationale for combination studies in early
breast cancer.
J Clin Oncol 17:2341-2354. r 1999 by American
Society of Clinical Oncology.
DESPITE ADVANCES IN screening, locoregional treat-ment, and systemic adjuvant therapy for breast can-
cer, metastatic relapse is still common. The recent meta-
analysis of adjuvant breast cancer trials indicated that after
adjuvant polychemotherapy, 40% of patients had a recur-
rence, many of them, it can be assumed, with distant
metastases.1 For patients with advanced breast cancer whose
tumors express the estrogen and/or progesterone receptor,
endocrine therapy, as well as chemotherapy, can provide
palliation, but for patients with receptor-negative cancers,
those whose disease has become resistant to endocrine
manipulations, and those in whom impending organ failure
necessitates a rapid response, cytotoxic chemotherapy is
generally the first treatment option to be considered.
Since its introduction in the early 1970s, doxorubicin has
generally been considered to be the most active chemothera-
peutic agent in the treatment of metastatic breast cancer. In
particular, in patients with advanced breast cancer who have
received previous alkylating agent chemotherapy, doxorubi-
cin monotherapy has produced response rates of 25% to
33% at doses ranging from 60 to 75 mg/m2, with median
times to progression between 2.7 and 4.5 months.2-7 Mono-
therapy with epirubicin or mitoxantrone4,7-10 has not im-
proved further the results obtained with doxorubicin as a
single agent in this patient population.
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Despite doxorubicin being considered standard treatment
for advanced breast cancer, it is associated with a number of
troublesome side effects that limit its use in the palliative
setting; these include prominent myelotoxicity, nausea,
vomiting, mucositis, and cumulative dose-dependent and
generally irreversible cardiotoxicity.11-15 The risk of develop-
ing congestive heart failure (CHF) increases from 7% at a
total doxorubicin dose of 550 mg/m2 to 15% at 600 mg/m2
and 30% at 700 mg/m2 15; however, CHF has also been
reported at doses as low as 40 mg/m2.14 CHF typically
becomes apparent 4 to 18 weeks after the last anthracycline
dose, but it may occur during treatment or years later.15
The results of phase II clinical trials have shown that
docetaxel (Taxotere; Rhoˆne-Poulenc Rorer, Collegeville,
PA; 100 mg/m2/1-hour infusion) is a highly active agent for
the treatment of patients with advanced breast cancer,
including those with visceral involvement, liver involve-
ment, and resistance to previous chemotherapy. Phase II
studies in prospectively defined patient populations with and
without previous anthracycline therapy yielded response
rates of 43% and 61% and median times to progression of 4
and 5 months, in the respective patient populations.16-18
Docetaxel is associated with a cumulative toxicity, namely
fluid retention. Docetaxel-related fluid retention is predict-
able (median dose to onset between 400 and 500 mg/m2 in
all phase II studies using corticosteroid premedication),
reversible (median time to resolution between 16 and 20
weeks), and has not been lethal, with severe symptoms in
only 5% to 6% of patients.17-19
To clarify the above observations, a phase III study
comparing docetaxel with doxorubicin was performed to
evaluate the benefit and risks of these two agents in the
treatment of patients with advanced breast cancer who had
received previous alkylating agent chemotherapy.
PATIENTS AND METHODS
Patient Population
Women with histologically or cytologically confirmed metastatic
breast cancer who met the following eligibility criteria were included in
the study: 18 to 75 years of age, measurable or nonmeasurable-but-
assessable (evaluable) disease, performance status of at least 60
(Karnofsky index), and a life expectancy of at least 12 weeks. All
patients had to have received previous alkylating agent chemotherapy
(eg, cyclophosphamide, methotrexate, and fluorouracil [CMF], or its
variants) either in the adjuvant setting or for advanced disease. Patients
were classified as resistant or nonresistant to previous alkylating agent
chemotherapy, as follows: resistant, relapse during or within 12 months
of adjuvant therapy or progression during or within 30 days of last cycle
of chemotherapy for advanced disease, regardless of response; nonresis-
tant, relapse more than 12 months after adjuvant therapy or progression
more than 1 month after last cycle of chemotherapy. Specific criteria for
exclusion were as follows: more than one line of chemotherapy for
advanced or metastatic disease; previous treatment with anthracyclines,
anthracenes, or taxoids; no alkylating agent in last chemotherapeutic
regimen; history or presence of brain or leptomeningeal metastases;
previous or concurrent malignancies, with the exception of adequately
treated in situ carcinoma of the uterine cervix and cured nonmelanoma
skin cancer; inadequately assessable disease, defined as patients with
only osteoblastic skeletal lesions, a single osteolytic lesion, lymph-
edema, pulmonary lymphangitic metastases, pleural effusion, and/or
ascites as the only manifestation of disease; and symptomatic peripheral
neuropathy of grade 2 or more according to National Cancer Institute
Common Toxicity Criteria (NCI-CTC).
Patients were also excluded if they had an absolute neutrophil count
of less than 2 3 109/L, a platelet count below 100 3 109/L, a total
bilirubin level above the upper normal limit (UNL); AST or ALT level
more than three times the UNL and alkaline phosphatase level more
than six times the UNL; AST or ALT more than 1.5 times the UNL and
alkaline phosphatase level more than 2.5 times the UNL; serum
creatinine level more than 1.5 times the UNL; a resting left ventricular
ejection fraction (LVEF) of less than 50% (or below the lower normal
limit of the institution) as measured by echocardiography or radionu-
clide angiocardiography. Concomitant bisphosphonate treatment was
not allowed unless it had been initiated more than 3 months before the
start of the study.
Patients were recruited from 41 centers worldwide. Ethics committee
approval and informed patient consent were obtained before the start of
the trial. Study investigators other than those listed as authors are shown
in the Appendix.
Study Design
This was a randomized, multicenter, nonblinded, prospective, phase
III study. The randomization was centralized and stratified for treatment
arm by institution. There was no stratification for any prognostic factor.
Patients were assigned randomly to receive an intravenous infusion of
docetaxel 100 mg/m2 for 1 hour every 3 weeks or doxorubicin 75 mg/m2
for 15 to 20 minutes every 3 weeks. Premedication for hypersensitivity
reactions and fluid retention was specified for patients in the docetaxel
group only and consisted of oral dexamethasone 8 mg, given 13 hours, 7
hours, and 1 hour before docetaxel infusion and for a further 4 days at a
dose of 8 mg twice daily, starting immediately after docetaxel infusion.
Antiemetic premedication was given according to each center’s normal
practice. Prophylactic administration of granulocyte-colony stimulating
factor (G-CSF) was not allowed in either treatment group.
The highest feasible dose of doxorubicin, without G-CSF support,
was chosen to provide a reliable test of the single-agent activity of
docetaxel. A maximum of seven treatment cycles was set for both
groups because of the unacceptable incidence of CHF associated with a
cumulative doxorubicin dose of more than 550 mg/m2.14 Fewer cycles
were given if progression or unacceptable toxicity occurred. If a patient
failed to respond to the assigned treatment, further treatment was at the
discretion of the investigator. A decrease in LVEF of 10% (absolute
units) in association with a decline below 50% (Schwartz criteria)20 was
specified as the criterion for treatment discontinuation based on LVEF
assessments. Patients withdrawn from the study before progression
could not receive other antitumor therapy until progression was
documented, unless considered necessary by the investigator. Patients
were observed for 1 month after their last study treatment infusion to
document any late adverse events, with a follow-up visit every 3 months
until death, to document time to progression (TTP) and survival.
Dose reductions were planned for severe hematologic and nonhema-
tologic toxicities other than alopecia and anemia, graded according to
NCI-CTC. A maximum of two dose reductions were allowed per
patient, ie, from 100 to 75 mg/m2 and from 75 to 55 mg/m2 for docetaxel
and from 75 to 60 mg/m2 and from 60 to 45 mg/m2 for doxorubicin.
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Assessments
A complete tumor assessment, consisting of chest radiography and/or
chest computed tomography scan, bone scintigraphy, bone radiography
(if bone scintigraphy was positive), abdominal computed tomography
or ultrasonography, and physical examination, was performed in the 3
weeks before the first infusion of study medication. Bone scintigraphy
could be performed 4 weeks before the first infusion of study
medication. All measurable and evaluable lesions were to be assessed at
the end of cycles 2, 4, and 7 or at discontinuation of study treatment, and
then at least every 3 months until progression in the follow-up period.
Response was classified according to World Health Organization
criteria.21 Complete response (no detectable tumor, including bone) and
partial response ($ 50% reduction) had to be confirmed by a second
evaluation more than 28 days later. Patients with no progression at least
6 weeks after the start of therapy were considered to have stabilization
of disease. Patients with disease progression ($ 25% increase in size of
any lesion or a new lesion) before or at the end of the second treatment
cycle were considered to have early progression and were classified as
having progressive disease for response to treatment. All patients with a
radiographic record of tumor assessments were reviewed by an
independent panel of two radiologists and an oncologist (the results of
this review are reported).
Weekly blood counts were performed. Febrile neutropenia was
defined as fever (38°C or more) with grade 4 neutropenia requiring
intravenous antibiotics and/or hospitalization, without documented
infection.
An initial assessment of LVEF was made during the 2 weeks before
study entry, using a multiple gated angioscintigraphy (MUGA) scan or
echocardiography; LVEF was re-assessed after a 400-mg/m2 cumula-
tive dose in the doxorubicin group, and when the patient stopped study
treatment for any reason in either treatment group, using the same
method as at baseline. No cumulative dose-specific evaluation was
planned for the docetaxel arm because of the absence of cardiac toxicity
in all previous reports. Fluid retention was monitored at each cycle and
during follow-up until resolution. Severity of fluid retention was defined
according to the following scale: mild, asymptomatic edema or
effusion; moderate, edema that was pronounced or caused moderate
functional impairment, or effusion that was symptomatic and possibly
required drainage; and severe, edema that caused significant impair-
ment or effusion causing dyspnea that required urgent drainage.
Quality of life (QOL) was assessed using the European Organization
for Research and Treatment of Cancer (EORTC) Quality of Life
Questionnaire–C30, a 30-item core questionnaire,22,23 which was com-
pleted by patients in the 3 days before their first infusion, before they
received each cycle of study treatment, and at each visit during
follow-up, up to and including the occurrence of first progression. The
change in Karnofsky performance status (KPS) was used to assess
patient condition from the physician’s point of view.
Statistical Methodology and Analysis
The initial sample size of 156 patients per treatment group was
selected to detect a 50% increase in median TTP with a 5% two-sided
type I error and a 90% power. Accrual was expected to take 15 months.
The sample size took into account the possibility that 10% of patients
would not be assessable.
The intention-to-treat (ITT) population was defined as all randomized
patients. The eligible and assessable population consisted of all patients
who did not have a major deviation from the eligibility criteria, did not
have an on-study deviation, received at least two cycles of treatment,
and had at least one complete tumor assessment after the baseline
evaluation. Analyses of response rate and TTP were performed on both
the ITT population and on the eligible and assessable patient population.
Analyses of survival and time to treatment failure (TTF) were per-
formed on the ITT population only. Safety analyses were performed on
all treated patients.
Response rate was defined as the percentage of patients in each
treatment group who achieved a complete or partial response. TTP was
calculated from the date of randomization until progression or death.
Patients who received any further antitumor treatment before disease
progression were censored at the date of the last tumor assessment
before the start date of the new antitumor treatment. TTF was calculated
from the date of randomization to the date of progression, death for any
reason, withdrawal due to an adverse event, patient refusal, or further
anticancer therapy before documentation of progression, whichever
occurred first. Survival was calculated from the date of randomization
to the date of death for any reason.
Categorical data, such as response rate and adverse events, were
compared using the x2 test. Confidence intervals for response rates were
computed using the exact method. Time-to-event parameters were
analyzed using the Kaplan-Meier method. Efficacy parameters, such as
TTP, TTF, and survival, were compared using the log-rank test and the
Wilcoxon test. Multivariate analyses were performed on TTP, TTF, and
survival using a Cox proportional hazards model and on response rate
using a logistic regression model, to analyze the treatment effect when
adjusting for prospectively chosen covariates (line of previous chemo-
therapy for advanced disease [none, one]; resistance to previous
alkylating agents [not resistant, resistant]; age [# 49 years, $ 50 years];
KPS [100%, 90% to 80%, # 70%]; time from first diagnosis to
randomization [# 12 months, . 12 months]; time from last chemother-
apy to randomization [# 3, 3 to 12, . 12 months]; visceral, liver, or
bone involvement [no, yes]; number of organs involved [1, 2, $ 3];
intention of previous hormonal therapy [none, adjuvant, advanced 6
adjuvant]; number of lines of hormonal therapy for advanced disease
[none, 1, $ 2]; previous chemotherapy received as adjuvant [no, yes];
setting(s) in which previous chemotherapy was received [adjuvant,
advanced, adjuvant 1 advanced]; and baseline QOL score [continuous
variable]) or for the most significant covariates using the Collett
selection strategy.24
Safety analyses were performed on all treated patients. For hemato-
logic and biochemical changes, drug safety was analyzed directly from
reported laboratory parameters. Analysis of hematologic parameters
was performed for treated patients who had at least one blood count
assessed between the 2nd and 19th days of any cycle. Clinical signs and
symptoms experienced on treatment were graded according to NCI-
CTC or as mild, moderate, or severe (Coding Symbols for Thesaurus of
Adverse Reaction Terms [COSTART] classification) if NCI-CTC were
not appropriate.
Two types of analysis were performed on LVEF: relative decrease in
LVEF from baseline according to the NCI-CTC, and absolute decrease
in LVEF from baseline according to the Schwartz criteria, that is, a
decrease in LVEF of at least 10 absolute percentage points and below
the lower normal limit.
All ITT patients who had an assessable baseline questionnaire and at
least one further measurable assessment on-study were considered
assessable for QOL. The primary QOL variable was the global health
score, and the principal secondary variable was the physical functioning
score; the other 13 dimensions in the questionnaire were also analyzed.
The Wilcoxon rank sum test was used to compare differences in the
change from baseline to the average of the postbaseline measures
between the two treatment groups. Median times to worsening of KPS
by 20 points were analyzed by the Kaplan-Meier method.
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In addition to the above analyses, which were proposed before
initiation of the study, a sensitivity analysis was performed to examine
the impact of missing data on the results. All QOL assessments within 6
months of randomization were included in the following analyses.
Three methods were considered for the two major QOL measures:
global QOL and physical functioning. All methods used a mixed effect
model, which accommodated the mistimed QOL assessments. The first
method assumes the data are missing at random.25 Additional sensitivity
analyses were performed using two different models assuming that the
censoring was not random. The first of these methods is an example of a
selection model.26 The concept underlying this model is that patients
whose QOL declines more rapidly are more likely to be censored
earlier, either because of disease progression or death. The second
method is an example of a pattern mixture model.27 This model was
estimated using the same mixed effects model within strata defined by a
propensity score for dropout. Treatment group, prior chemotherapy,
visceral involvement at baseline, performance status, and age predicted
dropout before completion of seven cycles.
All analyses were performed using the SAS software package (SAS
Institute, Cary, NC). All P values were two-sided. Differences at P #
.05 were considered statistically significant.
RESULTS
Patients
Of the 326 patients randomized to receive study medica-
tion (docetaxel, n 5 161; doxorubicin, n 5 165), 159
patients in the docetaxel group and 163 patients in the
doxorubicin group actually received treatment. The two
patients in each group who did not receive study medication
were included in the efficacy analyses, including the survival
analysis.
The first patient was randomized on July 4, 1994, and the
last on January 24, 1997. This report is based on data from
all 326 randomized patients with follow-up until September
15, 1997. The median follow-up was 23 months, as deter-
mined by the reverse-survival Kaplan-Meier method.
In the docetaxel arm, four patients were considered
ineligible: one patient had received two prior regimens of
CMF for advanced disease, one patient had thrombocytope-
nia at baseline, one patient had a concomitant treatment with
bisphosphonates started just before the study, and one
patient had one lytic bone lesion as the only manifestation of
disease. In the doxorubicin arm, six patients were considered
ineligible: one patient had received two prior regimens for
advanced disease, one patient had thrombocytopenia at
baseline, one patient started treatment with bisphosphonates
just before the study, one patient retrospectively had metas-
tases from melanoma, one patient had only nonassessable
lesions, and one patient did not receive an alkylating
agent–containing regimen as the last chemotherapy.
There were no statistically significant differences in the
pretreatment characteristics of the patients randomized to
each group (Table 1). All patients had metastatic disease, and
the most important negative prognostic factors (age , 50
years, visceral and liver involvement, involvement of three
or more organs, previous adjuvant chemotherapy, and resis-
tance to previous chemotherapy) were well represented and
equal in the two groups. There was a slight imbalance in the
proportions of patients with bone metastases (docetaxel,
55%; doxorubicin, 63%; P 5 .12). Slightly more patients in
the docetaxel group had received previous chemotherapy in





No. % No. %
Age, years
, 35 4 2 5 3
35-49 60 37 59 36
50-65 76 47 80 48







No. of organs involved
1 35 22 32 19
2 55 34 62 38
$ 3 71 44 71 43
Sites of metastases
Only soft tissue 14 9 20 12
Bone 89 55 104 63
Viscera 121 75 126 76
Liver 70 43 66 40
At least one measurable lesion 129 80 129 78
Intention of previous chemo-
therapy
Adjuvant only 82 51 70 42
Relapse within 12 months 27 17 27 16
Relapse after 12 months 55 34 43 26
Advanced only 70 43 80 49
Adjuvant 1 advanced 9 6 15 9
Response to previous chemo-
therapy
Resistant* 76 47 85 52
Not resistant† 85 53 80 48
Intention of previous hormonal
therapy
Adjuvant only 40 25 30 19
Advanced only 53 33 52 32
Adjuvant 1 advanced 20 12 33 20




*Relapse during adjuvant therapy, progression as best response, relapse
within 12 months of end of adjuvant therapy, or progression during therapy
after complete response, partial response, or no change.
†Relapse more than 12 months after adjuvant therapy or progression more
than 1 month after complete response, partial response, or no change.
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the adjuvant setting only; consequently, more patients in the
doxorubicin group had received previous chemotherapy for
advanced disease only, but the difference was not statisti-
cally significant (P 5 .12). As described in Statistical
Methodology and Analysis, all prognostic factors were
included in the multivariate analysis.
Exposure to Study Medication
The median number of treatment cycles administered was
higher in the docetaxel group than in the doxorubicin group
(seven cycles [range, one to 11] v six cycles [range, one to
seven], respectively). The range of cycles exceeded seven in
the docetaxel group because there were eight patients for
whom the investigator considered continuation of treatment
to be in their best interest. The median relative dose-
intensity was 0.97 (range, 0.05 to 1.07) for docetaxel and
0.95 (range, 0.49 to 1.05) for doxorubicin.
Overall, 130 patients completed the maximum number of
treatment cycles in accordance with the protocol, 74 in the
docetaxel group and 56 in the doxorubicin group (46% v
34%, respectively; P 5 .027). Reasons for early discontinu-
ation were as follows: disease progression (docetaxel, 30%;
doxorubicin, 36%); adverse events (docetaxel, 12%; doxoru-
bicin, 16%); withdrawal of consent (docetaxel, 3%; doxoru-
bicin, 7%); death (docetaxel, 3%; doxorubicin, 2%); proto-
col violation (docetaxel, 1%; doxorubicin, 1%); and other
(docetaxel, 5%; doxorubicin, 4%). Some patients in each
group were still responding or had stable disease at the end
of the seven treatment cycles planned in the protocol
(doxorubicin, 45 patients [27%]; docetaxel, 58 patients,
[36%]).
The adverse events that resulted most frequently in
discontinuation in the doxorubicin group were cardiac
toxicity (15 patients; 9%) and hematologic toxicity (six
patients; 4%). In the docetaxel group, the most frequent
were neurologic toxicity (five patients; 3%), allergy (three
patients; 2%), and peripheral edema (three patients; 2%). Of
the 15 patients who discontinued doxorubicin treatment
because of cardiac toxicity, three withdrew because of
clinical CHF; the other 12 patients had a decrease in LVEF
according to the Schwartz criteria. Two of these patients
developed clinical CHF during follow-up. Another patient
who developed clinical CHF during follow-up did not
discontinue because of cardiac toxicity. Patients who experi-
enced a decrease in LVEF meeting the Schwartz criteria but
did not discontinue because of cardiac toxicity, had the
decrease assessed at treatment completion or discontinua-
tion for a reason other than cardiac toxicity.
Fewer treatment cycles were delayed by at least 3 days in
the docetaxel group than in the doxorubicin group (7% v
15%, respectively). In addition, fewer treatment cycles were
delayed because of treatment-related adverse events in the
docetaxel group (21 cycles, 2%, v 89 cycles, 11%, respec-
tively). Specifically, hematologic toxicity (mostly low neu-
trophil counts) was the reason for treatment delay in six
patients (3.7%) and nine cycles (0.9%) in the docetaxel
group and in 43 patients (26.3%) and 69 cycles (8.2%) in the
doxorubicin group.
The study medication dose was reduced at least once in a
similar number of treatment cycles in each group (docetaxel,
47 cycles, 5%; doxorubicin, 40 cycles, 5%). The main
reason for dose reduction was hematologic toxicity (65% of
dose-reduced cycles in the doxorubicin group and 45% of
dose-reduced cycles in the docetaxel group).
Effıcacy
The overall response rate (complete responses plus partial
responses) was significantly higher with docetaxel than with
doxorubicin for both randomized (47.8% v 33.3%, respec-
tively; P 5 .008) and assessable patients (52.0% v 37.4%,
respectively; P 5 .012; Table 2). The difference in the
overall response rate between the two treatment arms was
14.5% (95% confidence interval [CI], 3.9% to 25.0%). The
complete response rate was higher in the docetaxel group
than in the doxorubicin group, and fewer patients in the
docetaxel group had progressive disease without any re-
sponse or stabilization. In the multivariate analysis, a
significant treatment effect in favor of docetaxel was seen
when adjusting for all covariates (odds ratio, 1.8; 95% CI,
1.1 to 2.9; P 5 .024) or for the most important ones using the
Collett strategy (odds ratio, 1.7; 95% CI, 1.1 to 2.8; P 5
.027). The variables identified for inclusion in the Collett
Table 2. Response to Treatment
Efficacy Variable
Randomized Patients (%) Assessable Patients (%)
Docetaxel (n 5 161) Doxorubicin (n 5 165) Docetaxel (n 5 148) Doxorubicin (n 5 147)
Response to treatment
Complete response 6.8 4.2 7.4 4.8
Overall response rate* 47.8 33.3 52.0 37.4
95% CI 40.1%-55.5% 26.1%-40.5% 44.0-60.1% 29.6%-45.2%
Progression 12.4 22.4 12.2 23.8
Not assessable 5.6 6.7 — —
*Overall response rate includes complete responses plus partial responses (P 5 .008 for randomized patients, P 5 .012 for assessable patients).
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analysis of response rate were time from last chemotherapy
to randomization, baseline QOL score, intent of prior
chemotherapy, bone involvement, and treatment arm. Doce-
taxel produced a higher response rate than doxorubicin in
almost all subgroups analyzed, especially in patients with a
poor prognosis because of liver involvement or resistance to
previous alkylating agents (Fig 1). All patients had normal
liver functions or mildly abnormal liver functions, as stated
in the protocol entry criteria, thus representing docetaxel
effectiveness in patients with liver metastases and relatively
normal liver function.
Median TTP was longer in the docetaxel group than in the
doxorubicin group for both randomized (26 weeks v 21
weeks, respectively; Fig 2) and assessable patients (27
weeks v 23 weeks, respectively), although the difference
between treatment groups did not reach statistical signifi-
cance according to either the log-rank or Wilcoxon test. In
the multivariate analysis, no significant difference was found
in TTP between the two groups when adjusting for all
covariates or for the most important ones (risk ratio, 1.0;
95% CI, 0.8 to 1.3). As noted above, eight patients in the
docetaxel group received more than seven cycles. An
additional analysis of TTP, censoring these patients at cycle
7, produced the same results.
Median TTF was longer in the docetaxel group (22
weeks) than in the doxorubicin group (18 weeks); the
difference between groups was significant according to the
Wilcoxon test (P 5 .0137) but not by the log-rank test (Fig
3). In the multivariate analysis, there was no significant
difference between the two groups when adjusting for all
covariates or for the most important ones (risk ratio, 1.1;
95% CI, 0.9 to 1.4).
The most important variables identified for the Collett
analysis of TTP, TTF, and survival were performance status,
baseline QOL score, time from last chemotherapy to random-
ization, and number of organs involved (number of organs
involved was not selected for TTF).
The median overall survival of all randomized patients
was similar in the two treatment groups (docetaxel, 15
months; doxorubicin, 14 months; Fig 4). In the multivariate
analysis, no significant difference was found between the
two groups when adjusting for all covariates or for the most
important ones (risk ratio, 1.0; 95% CI, 0.8 to 1.3). No
cross-over was planned, but 26% of patients in the doxorubi-
cin group received taxoid-containing therapy, and 28% of
patients in the docetaxel group received anthracycline-
containing therapy as the first anticancer treatment after
study treatment. No activity or safety data regarding the
cross-over treatments were collected. The difference be-
tween treatment groups remained not significant when
overall survival was adjusted for the cross-over treatment as
a time-dependent covariate.
Safety
The incidence of toxic deaths was higher in the doxorubi-
cin group (3%) than in the docetaxel group (1.2%). Five
patients died in the doxorubicin group: one death occurred
due to infection within 30 days of the last infusion; the
Fig 1. Odds ratio of response,
docetaxel versus doxorubicin (Doc,
docetaxel; Dox, doxorubicin; CT,
chemotherapy).
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Fig 2. Kaplan-Meier estimate of
the cumulative probability of remain-
ing free from disease progression in
each treatment group (ITT popula-
tion) (docetaxel, n 5 161, d; doxo-
rubicin, n 5 165, s).
Fig 3. Kaplan-Meier estimate of
the cumulative probability of remain-
ing free from treatment failure in
each treatment group (ITT popula-
tion) (docetaxel, n 5 161, d; doxo-
rubicin, n 5 165, s).
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remaining four patients died due to doxorubicin-related
cardiac toxicity more than 30 days after the last infusion
(three patients developed CHF at cumulative doxorubicin
doses of 387, 437, and 450 mg/m2, and one patient with a
history of hypertension and cardiomegaly on pretreatment
chest x-ray developed tachycardia at the same time as
disease progression [including pericarditis carcinomatosa] at
a cumulative doxorubicin dose of 536 mg/m2). In the
docetaxel group, one patient died due to infection, and one
died due to disease progression associated with liver failure
in a patient whose liver enzyme levels rose above entry level
eligibility in the week between randomization and first
treatment and in whom the contribution of treatment to the
onset of liver failure could not be ruled out.
Hematologic adverse events related to study medication
are presented in Table 3. Grade 4 neutropenia was the most
frequent hematologic toxicity and was similar in both
groups; however, the incidence of severe neutropenic com-
plications (febrile neutropenia and severe infection) was
significantly higher in the doxorubicin group (doxorubicin,
16%; docetaxel, 8%; P 5 .02). The median time to
neutropenic nadir was 7 days (range, 5 to 15 days) in the
docetaxel group and 14 days (range, 7 to 19 days) in the
doxorubicin group. The time taken to recover from neutrope-
nic nadir to grade 0 or 1 neutropenia was 7 days in both
treatment groups. However, the fact that the study design
required only weekly blood counts limits this analysis. The
incidence of grade 3 or 4 anemia was significantly higher in
the doxorubicin group, as was the proportion of patients who
required an RBC transfusion. Thrombocytopenia (overall
and severe) was significantly more frequent in the doxorubi-
cin group but did not induce significant clinical complica-
tions.
Nonhematologic adverse events related to study medica-
tion are presented in Table 4. Nausea, vomiting, and
stomatitis occurred more frequently in the doxorubicin
group, whereas diarrhea, skin toxicity, allergy, nail disorder,
and neurotoxicity occurred more frequently in the docetaxel
group. The incidences of asthenia and alopecia were similar
in the two groups.
With regard to dose-cumulative toxicities (Table 5), fluid
retention in the docetaxel group was counterbalanced by
cardiac toxicity in the doxorubicin group. Six patients
(3.7%) in the doxorubicin group developed CHF (three
during treatment and three during follow-up; Table 6). All of
these patients had received a cumulative doxorubicin dose
below what is normally considered a safe dose (, 460
mg/m2), and only one patient had risk factors in her history
(73 years of age and hypertension). Among the 86 patients
being treated with docetaxel who were assessable for LVEF
decrease, 57% were evaluated by MUGA scan, and among
the 101 patients who were assessable in the doxorubicin
treatment arm, 54% were evaluated by MUGA scan. The
remainder of patients, on both arms, assessable for LVEF
Fig 4. Kaplan-Meier estimate of
the cumulative probability of sur-
vival in each treatment group (ITT
population) (docetaxel, n 5 161, d;
doxorubicin, n 5 165, s).
2348 CHAN ET AL
Downloaded from ascopubs.org by University of Queensland on February 1, 2017 from 130.102.082.083
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
were assessed by echocardiography at all assessments. Of
the 29 patients in the doxorubicin group who had a reduction
in LVEF that met the Schwartz criteria, only 10 had received
a cumulative doxorubicin dose of 460 mg/m2 or more; 16
had no risk factors for CHF, five had a history of hyperten-
sion, four had an effusion (pericardial or pleural) related to
disease, three had radiotherapy to the left breast, and one had
mediastinum tumor involvement. Of note, 20 of the 29
patients were detected after seven cycles.
Of the seven patients in the docetaxel group who had a
reduction in LVEF that met the Schwartz criteria, three had a
concomitant medical condition that may have accounted for
the decrease in LVEF (hypertension, radiotherapy of the left
chest wall that may have encompassed the heart, and
concomitant grade 4 pericardial effusion).
In the docetaxel group, the median cumulative dose to
onset of fluid retention was 478 mg/m2 (range, 51 to 8921
mg/m2). Of the 95 patients who experienced fluid retention,
74.7% experienced edema only, 15.8% experienced edema
and weight gain, and 6.3% experienced edema and pleural
effusion, and the remaining patients comprised individual
cases of all three symptoms, weight gain only, and edema
and pericardial effusion.
QOL
Overall compliance (defined as the ratio between the
number of patients assessable for QOL and the number of
patients on treatment at each cycle) was high (. 80%) and
similar in both groups for cycles 1 to 4, but it deteriorated in
the doxorubicin group at cycle 5 (docetaxel, 86%; doxorubi-
cin, 64%) and remained higher in the docetaxel group at
cycle 6 (74% v 69%, respectively). The cumulative propor-
tion of missing scores at each cycle (attrition rate) was
Table 3. Hematologic Adverse Events
Adverse Event
Docetaxel Doxorubicin
No. of Patients %* No. of Patients %*
Neutropenia
Overall 154 97.4 153 96.7
Grade 3 154 14.9 153 11.1
Grade 4 154 78.6 153 77.8
Febrile neutropenia† 159 5.7‡ 163 12.3
Infection grade 3/4 159 2.5 163 4.3
Anemia
Overall 158 88.6 161 93.2
Grade 3/4 158 4.4‡ 161 16.1
RBC transfusion 159 6.9‡ 163 20.9
Thrombocytopenia
Overall 158 4.4‡ 161 40.4
Grade 4 158 1.3‡ 161 7.5
*Incidence of events possibly/probably related to study medication.
†Fever $ grade 2 and grade 4 neutropenia requiring hospitalization
and/or intravenous antibiotics.
‡P # .05.
Table 4. Nonhematologic Adverse Events
Adverse Event
% of Patients†
Overall % of Patients*
% of Patients With










Nausea 39.6† 79.1 3.1† 14.1
Vomiting 22.6† 58.3 3.1† 12.3
Stomatitis 49.7 58.3 5.0† 12.3
Diarrhea 50.3† 17.2 10.7† 1.2
Skin toxicity 37.7† 7.4 1.9 0.6
Allergy 17.6† 5.5 2.5 1.2
Chronic
Alopecia 91.2 90.8 NA NA
Asthenia 59.7 56.4 14.5 12.3
Nail disorder 44.0† 4.9 2.5 0
Neurosensory 42.8† 5.5 5.0 0
Neuromotor 18.2† 2.5 5.0 0
*Incidence of events possibly/probably related to study medication.
†P # .05.
Table 5. Cumulative Toxicities
Docetaxel Patients
(n 5 159) (%)
Doxorubicin Patients
(n 5 163) (%)
Cardiac toxicity
CHF 0 3.7
LVEF decrease (Schwartz)* 8.1 28.7
LVEF decrease . 20%* 8.1 31.7
LVEF decrease . 40%* 0 16.0





Discontinuation rate 1.9 0
Lethal 0 0
Median time to recovery, weeks 19 NA
Number of patients assessable for LVEF: docetaxel, n 5 86; doxorubicin, n 5
101.



















1 15 6 437 Death* 54 35†
2 52 7 449 Improved 76 Not done
3 98 5 387 Death* 53 23†
4 197 6 450 Death* 65 Not done
5 44 6 454 Ongoing 70 23
6 39 6 456 Improved 60 47†
*More than 30 days after last infusion.
†Confirmed with repeated-measure analysis.
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higher in the doxorubicin group than in the docetaxel group
(eg, 34% v 25% and 56% v 43% at cycles 4 and 6,
respectively).
Mean decreases in global health and physical functioning
scores from baseline were not significantly different in the
two treatment groups (Fig 5). The median time to worsening
of the KPS by 20 points was not reached in either treatment
group, and changes from baseline per cycle were similar in
the two treatment groups; most patients (approximately
80%) had a stable KPS.
As described in Statistical Methodology and Analysis,
supplementary analyses were performed to examine the
sensitivity of the results to different assumptions about the
missing data, and specifically to consider the possibility of
nonignorable (nonrandom) censoring in the QOL assess-
ments. In comparisons of the two treatment groups, no
statistically significant treatment effect was found in global
QOL or physical functioning at 13, 19, or 26 weeks after
randomization across any of the three methods considered
(results not shown). The results of the three analytical
models on global QOL score do not show statistical
evidence in the data for nonrandom missingness, and the
estimates were stable across all analyses. It should be
emphasized, however, that the lack of statistical evidence in
the available data does not rule out the possibility of
nonrandom dropout throughout the study.
DISCUSSION
This is the first randomized trial in metastatic breast
cancer in which a chemotherapeutic agent (docetaxel 100
mg/m2/1-hour infusion) has produced a significantly higher
response rate than doxorubicin given at its highest feasible
dose (75 mg/m2/short intravenous infusion) without growth
factors.
The difference between docetaxel and doxorubicin was
confirmed by the logistic regression model on response rate;
the odds for response in a patient receiving docetaxel were
1.7 times higher than in a patient receiving doxorubicin
(adjusting for most important prognostic factors). A higher
probability of response may be of particular clinical impor-
Fig 5. Medians of the mean changes in
QOL scores from baseline (all assessable
patients) (docetaxel, n 5 142, d; doxorubi-
cin, n 5 143, s).
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tance in patients with liver metastases (before significant
liver impairment) or symptoms requiring urgent attention,
such as dyspnea caused by lymphangitic carcinomatosis. In
patients with rapidly deteriorating liver function tests, the
values should be re-assessed on the day of treatment to
confirm that these patients remain candidates for treatment.
In addition, more patients in the doxorubicin group had
progression of disease without any response or stabilization
of disease.
While a statistically significant difference in response rate
was shown, the study was powered to detect a difference of
50% in median TTP as the primary end point. A 25%
difference in favor of docetaxel was shown, but this did not
reach statistical significance as assessed by log-rank or
Wilcoxon test. TTF was statistically significantly in favor of
docetaxel by the Wilcoxon test (which gives more weight to
the earlier events with larger patient numbers), but it was not
significant as assessed by the log-rank test. Overall survival
was not different between the two groups.
The results of our study confirm the activity of docetaxel
100 mg/m2 reported in phase II studies. In five phase II
studies with a total of 154 patients untreated for metastatic
disease, docetaxel yielded a response rate of 61% (95% CI,
52% to 69%), with a median TTP of 4.9 months and a
median survival time of 16.4 months. In addition, in four
phase II studies involving a total of 134 patients resistant to
anthracyclines, docetaxel produced a response rate of 43%
(95% CI, 35% to 50%), with a median TTP of 4.3 months
and a median survival time of 10.6 months (ITT analysis).16
This study has shown that docetaxel has a consistently
high level of activity in patients with metastatic breast
cancer, regardless of negative prognostic factors; this was
not the case for doxorubicin. For example, docetaxel pro-
duced similar response rates in patients resistant and nonre-
sistant to a prior CMF regimen (47% and 48%, respec-
tively); doxorubicin, however, was less effective in resistant
patients than in nonresistant patients (25% v 43%, respec-
tively). This observation suggests that docetaxel does not
have clinical cross-resistance to previous CMF regimen.
The median TTP was longer in the docetaxel group,
although the difference was not statistically significant
(according to both log-rank test and multivariate analysis).
The shape of the curve (Fig 2) suggests that fewer patients
receiving docetaxel are likely to experience progression in
the first few treatment cycles, as compared with patients
receiving doxorubicin. This is supported by the results of the
Wilcoxon test, which were close to being significant,
although in the context of multiple testing.
The term treatment failure encompasses discontinuation
because of toxicity, in addition to disease progression (which
is described more specifically by TTP), and may therefore
provide a clinically important measurement of the time that
the patient is receiving, and possibly benefiting from,
treatment. In our study, the median TTF was longer in the
docetaxel group than in the doxorubicin group; the differ-
ence was statistically significant according to the Wilcoxon
test (P 5 .0137). The lower probability of failure in the first
few months of docetaxel therapy may reflect some benefit
over doxorubicin for the patient, but this was not seen in the
QOL results of our study. Further QOL studies focusing on
the moment when treatment failure occurs and the period
immediately afterward may be able to quantitate just how
meaningful this difference is to the patient.
The high rate of attrition limits interpretation of changes
in QOL scores from baseline, and any conclusions are
therefore drawn with caution. With these limitations, how-
ever, the evolution of QOL was not clinically significantly
different in the two groups and was relatively stable for the
entire duration of the two study treatments. In particular, it
was notable that the longer length of exposure to study
medication in the docetaxel group did not have a negative
impact on QOL. To ensure that more meaningful data are
obtained from future studies using QOL measurements, we
suggest that particular attention is paid to compliance at the
time of progression or early study discontinuation.
Our comparison of safety parameters favored docetaxel.
First, there were more toxic deaths in the doxorubicin group
than in the docetaxel group. In addition, doxorubicin-related
cardiac toxicity was in some cases life-threatening, unpredict-
able, and irreversible: clinical CHF was observed in six
doxorubicin patients at cumulative doses below 460 mg/m2,
which is commonly considered to be a safe cumulative dose.
Cardiac toxicity was also the most frequent reason for
discontinuation of doxorubicin treatment. The dose-cumula-
tive LVEF evaluation required for doxorubicin only may
have introduced a bias in these results. However, for
docetaxel patients, the low incidence of any LVEF decreases
(assessed at end of treatment) and the absence of any CHF
(assessed throughout the study) confirm that cardiac toxicity
is not associated with docetaxel and cardiac monitoring is
not required. In contrast, docetaxel-related fluid retention
was less likely to lead to treatment discontinuation and did
not cause any mortality.
As expected for the other nonhematologic toxicities,
doxorubicin patients experienced nausea, vomiting, and
stomatitis most frequently, whereas docetaxel patients expe-
rienced diarrhea, neurotoxicity, and skin and nail changes
most frequently. The lack of overlap in the nonhematologic
toxicities of docetaxel and doxorubicin suggests that these
two agents may be combined. Safety differences should be
taken into consideration when deciding on which drug is an
appropriate option for use as monotherapy.
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Although the incidence of grade 4 neutropenia is similarly
high with both drugs, docetaxel induces fewer neutropenic
complications (febrile neutropenia and severe infections).
This observation may be explained by the higher level of
stomatitis (overall and severe) in the doxorubicin group and
by the different neutropenic profiles as indicated by the
median number of days to nadir and the number of cycles
requiring treatment delay for hematologic reasons.
While the results of this study reflect a well-designed trial
based on data available at that time, there are two areas
where current clinical practice may not be reflected. The first
relates to the safety profile of docetaxel reported in our
study, which is for patients who had received a 5-day
regimen of corticosteroid premedication; a 3-day regimen is
now known to be equally effective and improves the overall
safety profile of docetaxel, particularly with regard to
mucositis, diarrhea, and infection.19 The second area of
difference relates to the seven-cycle limit, which was
necessary because of the cumulative toxicity of doxorubicin
and was imposed in both treatment groups to provide a
balanced study. In the docetaxel group, over 50 patients
were still responding when treatment was stopped in accor-
dance with the protocol. Continuation of treatment with
docetaxel is an option because of the low rate of discontinu-
ation due to fluid retention associated with cumulative dose.
Further studies are needed to determine whether additional
cycles are beneficial and produce improvements in TTP and
survival times. Duration of therapy may be an important
variable not considered in this study; indeed, it has been
found to have an effect in other studies with various
chemotherapy regimens.28-30
There is no published controlled randomized trial compar-
ing 60 and 75 mg/m2 of doxorubicin in metastatic breast
cancer. There is a small phase II comparison by Carmo-
Pereira et al31 in which they report a significant difference in
response rates and survival when comparing 35 mg/m2/3
weeks (16 cycles) with 70 mg/m2/3 weeks (eight cycles).
The 75-mg/m2 dose of doxorubicin was chosen because on
the basis of previous reports, it seemed to have a neutropenia
level similar to that of docetaxel at 100 mg/m2; neutropenia
is considered by some to be a surrogate for activity.
Doxorubicin 75 mg/m2 is the highest feasible dose without
growth factors. The results of our study show a similar
incidence and severity of neutropenia for both treatment arms,
confirming this to be a comparison of equineutropenic doses.
Studies comparing nonanthracycline, single-agent chemo-
therapy with doxorubicin monotherapy are rare. To our
knowledge, there is only one published large phase III trial
comparing doxorubicin with a nonanthracycline agent in a
patient population similar to ours.7 Doxorubicin 75 mg/m2/3
weeks was compared with mitoxantrone 14 mg/m2/3 weeks
in advanced breast cancer patients who had received a
previous alkylating agent–containing regimen. The overall
response rate was 29% in the doxorubicin group and 21% in
the mitoxantrone group, and the median TTP was 16 weeks
in the doxorubicin group and 11 weeks in the mitoxantrone
group. The response rate and median TTP produced by
docetaxel in our study compare favorably with these results.
The taxoid paclitaxel has also been compared with
doxorubicin in two recently reported, large-scale phase III
randomized studies.32,33 The first study was conducted by
the EORTC and compared paclitaxel 200 mg/m2/3-hour
infusion with doxorubicin 75 mg/m2.32 Of the 331 patients
recruited, 68% were chemotherapy-naive and the remaining
32% had received alkylating agent chemotherapy with
adjuvant intent. In our study, the patient population was
more heavily pretreated (all patients had received alkylating
agent chemotherapy with adjuvant intent or for advanced
disease, or both). In the EORTC study, doxorubicin pro-
duced a significantly higher response rate (41% v 25%; P 5
.003) and longer median progression-free survival time (7.5
months v 4.2 months; P , .001) than paclitaxel. Median
survival duration also favored doxorubicin (18 months v 15
months); the difference in survival was not significantly
different (P 5 .20).
The second study was a three-arm North American trial in
which doxorubicin 60 mg/m2 was compared with paclitaxel
175 mg/m2/24-hour infusion as well with the combination of
doxorubicin 50 mg/m2 plus paclitaxel 150 mg/m2/24-hour
infusion with G-CSF, in patients with advanced breast
cancer.33 Of 739 patients randomized, 69% were chemother-
apy-naive and 31% had received chemotherapy with adju-
vant intent. Although the patients were less heavily pre-
treated than in our study and a lower doxorubicin dose was
used, the response rate for paclitaxel in the assessable
population achieved only parity with that for doxorubicin
(34% v 36%, respectively).
A number of features confound any comparison of these
studies with ours, and no conclusions can be drawn from this
type of indirect comparison; the studies are reviewed merely
as a background perspective to our finding that docetaxel
produces a significantly higher response rate than doxorubi-
cin. In this regard, the results of an ongoing direct compari-
son of paclitaxel with docetaxel are awaited.
In conclusion, docetaxel given at its highest feasible dose
without G-CSF is at least as appropriate as doxorubicin
given at its highest feasible dose without G-CSF for patients
with metastatic breast cancer. Studies evaluating docetaxel
in the classic combination approach with doxorubicin or in a
sequential schedule are clearly warranted. The rapid develop-
ment of docetaxel for patients with early breast cancer
should be a clinical research priority.
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